Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 9.01 · 8-K

INTERPACE BIOSCIENCES INC

IDXGOTCEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On November 16, 2026, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended September 30, 2026. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.…

Filed Nov 17, 2026Accepted Nov 17, 2026, 4:15 PM ESTCIK 1054102Accession 0001493152-26-052840
Share

Company context

We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management. Due to the decision of CMS to cease reimbursement coverage of our PancraGEN® test for assessing the risk of pancreatic cyst progression to cancer on April 24, 2025 which resulted in specimens for first-line fluid chemistry and PancraGEN® testing not being accepted by the Company after May 2, 2025, we are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2.

Current securities

Historical securities (5)

Recent company filings

  1. RW filingNov 18, 2026
  2. 10-Q filingNov 16, 2026
  3. CERT filingNov 5, 2026
  4. 8-A12B filingNov 5, 2026
  5. S-1/A filingOct 30, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On November 16, 2026, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended September 30, 2026. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

Exhibit 99.1 Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results Q3 Revenue of $10.4 million Q3 Thyroid volume year-over-year increase of 7% Q3 Thyroid revenue year-over-year increase of 18% Trailing twelve-month thyroid revenue of $38.0 million, an increase of 13% on a comparable thyroid-only basis PARSIPPANY, NJ, November 16, 2026 (GLOBE NEWSWIRE) - Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCID: IDXG) today announced financial results for the third quarter ended September 30, 2026 and provided a business and financial update. Interpace generated Q3 2026 revenue of $10.4 million, up 18% year-over-year, a loss from continuing operations of $1.5 million compared to income from continuing operations of $1.0 million in the prior year, and produced Adjusted EBITDA of $2.1 million, or 20% of revenue. The loss from continuing operations of $1.5 million included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses. As previously disclosed, the Company discontinued its PancraGEN ® pancreatic testing business in May 2025 and now operates as a thyroid-only molecular diagn…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.